Kubota Pharmaceutical Holdings Co., Ltd. (KBBTF)
Kubota Pharmaceutical Holdings Co., Ltd. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Tokyo, JP. The stock last traded at $0.96, up 0.00% on the session, giving a market capitalisation of $24.1M. On trailing twelve-month figures it carries a trailing P/E of -7.25, a net margin of -3885.2%. Its beta of 1.18 implies it has historically moved more than the broad market.
Kubota Pharmaceutical Holdings Co., Ltd. operates globally, concentrating on the development of innovative drugs and medical devices within the ophthalmology sector. A key asset in its product pipeline is emixustat hydrochloride, which is currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. The company is also advancing a remote, patient self-monitoring optical coherence tomography (OCT) device designed for home use, intended to address conditions like wet age-related macular degeneration and diabetic macular edema, which are characterized by retinal swelling and reduced visual acuity. Furthermore, it is developing a wearable device aimed at controlling myopia. This Tokyo, Japan-based company was founded in 2002.
Kubota Pharmaceutical Holdings Co., Ltd. is most often compared with the following Healthcare names: